Neodyne Biosciences Issued 8th US Patent for embrace® Advanced Scar Therapy
MENLO PARK, Calif., March 20, 2014 /PRNewswire/ -- Neodyne Biosciences, a medical device company focused on the development and commercialization of innovative tissue repair devices to promote healing and minimize scar formation, announced today that it has been issued US Patent No. 8,674,164 entitled "Segmented Skin Treatment Systems and Methods."
This marks the 8th issued US patent in the Neodyne Biosciences portfolio and further supports the company's first product family, embrace® Advanced Scar Therapy, which received 510(k) clearance from the US Food and Drug Administration (FDA) and has been proven to significantly improve scar appearance in randomized, controlled studies.1,2
"We consider a strong patent portfolio to be a cornerstone of our company's foundation, and have made this a core value for the business," said Bill Beasley, President of Neodyne. "This issued patent represents another achievement towards that goal."
The newly issued patent is owned by Neodyne Biosciences and is accessible on the USPTO's website at www.uspto.gov.
About Neodyne Biosciences, Inc.
Neodyne Biosciences (www.neodynebio.com) is an evidence based company developing and commercializing innovative tissue repair devices to minimize scar formation, restoring both function and aesthetic appearance. The company is developing stress-shielding devices capable of controlling the mechanical wound environment to ameliorate post-surgical scarring. Although the etiology remains unclear, mechanical forces such as surrounding skin tension and body movement have been demonstrated to increase fibrosis and scar formation. It is estimated that approximately 80 million major surgical procedures are performed in the United States each year and 230 million performed worldwide. Patient frustration with post-surgical scarring spans a variety of procedures with many seeking means of prevention and treatment.
Neodyne Investor Relations Contacts:
Bill Beasley President/COO |
Michael Fanucchi Marketing |
1Lim AF, et al. The embrace Device Significantly Decreases Scarring Following Scar Revision Surgery in a Randomized Controlled Trial. Plast Reconstr Surg. 2014;133:398-405.
2Data on File, #003.
SOURCE Neodyne Biosciences Inc.
Share this article